ClinicalTrials.gg
CompletedNCT01465009Updated Dec 11, 2014

Placebo and Active Controlled Study to Compare the Efficacy of Aspirin and Paracetamol in Treatment of Sore Throat Associated With a Common Cold

A Phase 4 interventional study of Acetylsalicylic acid (Aspirin, BAYE4465) and Paracetamol in Common Cold, Pharyngitis and Tonsillitis, sponsored by Bayer. Completed at 8 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-11.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
508
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Common Cold with a site in United Kingdom — none open to participants now, 1 under way, none of them phase 3. Common Cold · United Kingdom.

Enrollment
3rd of 20
508 · median 89
Started
2003
the only one that year
Phase 4
5 of 20
none open now
Registered
6th of 20
by date
Lead sponsor
2 of 20
Bayer

Among the 20 studies in Common Cold with a site in United Kingdom, this one is the 3rd largest by enrollment, is the only one that started in 2003, is one of 5 in phase 4, and was the 6th registered.

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Open to participants now

None of the 20 studies in Common Cold with a site in United Kingdom is open now. The open studies under Common Cold, anywhere →

Who these studies take

Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Common Cold with a site in United Kingdom as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of 1000 mg Aspirin (study medication) by comparing 1000 mg Paracetamol (study medication) in treating the symptoms of sore throat associated with a common cold. The study is designed to develop a treatment method against sore throat associated with a common cold which will have more advantages for patients than the methods that are currently available.

03

Conditions studied

  • Common Cold
  • Pharyngitis
  • Tonsillitis

Keywords

  • Sore Throat
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients
  • Onset of common cold within the past 5 days
  • Current sore throat
  • Confirmed presence of a tonsillo-pharyngitis

Exclusion criteria

Exclusion Criteria:

  • to acetylsalicylic acid, salicylates, paracetamol, or any other NSAID
  • Pregnant or lactating women
  • History or acute state of peptic ulceration or gastrointestinal bleeding
  • History of bleeding tendency
  • History of asthma
  • Inability to breathe through the nose or a history of chronic mouth breathing
  • Other exclusion criteria may apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
508 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Acetylsalicylic acid (Aspirin, BAYE4465)

  • Active comparator
    Arm 2

    Drug: Paracetamol

  • Placebo comparator
    Arm 3

    Drug: Placebo

Interventions

  • Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol

  • Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid

  • DrugPlacebo

    Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol

06

What researchers measure

Primary outcomes

  1. Pain intensity difference to baseline of Acetylsalicylic Acid in comparison to Paracetamol

    Time frame: For 6 hours after drug intake

Secondary outcomes

  1. Pain intensity difference to baseline of Acetylsalicylic Acid in comparison to Placebo

    Time frame: For 6 hours after drug intake

  2. Total pain relief of Acetylsalicylic Acid in comparison to Paracetamol

    Time frame: For 6 hours after drug intake

  3. Total pain relief of Acetylsalicylic Acid in comparison to Placebo

    Time frame: For 6 hours after drug intake

  4. Evaluation of Upper Respiratory Tract Infection symtoms

    Time frame: 2 hours after drug intake

  5. Adverse Event collection

    Time frame: Up to 17 days after Screening

07

Study locations

8 sites
  • Reading, Berkshire RG2 7AG, United Kingdom
  • Manchester, Greater Manchester M15 6SX, United Kingdom
  • Chorley, Lancashire PR7 1NY, United Kingdom
  • Wigan, Lancashire WN6 9EW, United Kingdom
  • Liverpool, Merseyside L1 9AD, United Kingdom
  • Liverpool, Merseyside L22 0LG, United Kingdom
  • Cardiff, South Glamorgan CF1 3US, United Kingdom
  • Birmingham, West Midlands B15 2SQ, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2011
First posted
Nov 4, 2011
Start
Nov 2003
CompletionActual
Mar 2005
Last update
Dec 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01465009
Lead sponsor
Bayer
First posted
Nov 4, 2011
Start date
Nov 2003
Completion
Mar 2005
Last update
Dec 11, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion